NCT03829345 - A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 2, 2019

Primary Completion Date

February 14, 2021

Study Completion Date

February 14, 2022

Conditions

Oesophageal CancerGastro-Oesophageal Junction CancerGastric Cancer

Interventions

DRUG

Olaparib

Patients will be administered olaparib orally twice daily (BD) at 300mg continuously for each 28 day cycle.

Trial Locations (2)

RECRUITING

Claire Saffery, Sutton

RECRUITING

Claire Saffery, Sutton